Clinical Trial Update: Pembrolizumab in Treating Patients With Metastatic Castration Resistant Prostate Cancer Previously Treated With Enzalutamide [Phase 2]

View source ↗

Summary

This Phase 2 trial assesses pembrolizumab in patients with metastatic castration-resistant prostate cancer who were previously treated with enzalutamide; result…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Castration-resistant Prostate Cancer
• Prostate Cancer

Drugs mentioned

• KEYTRUDA (PEMBROLIZUMAB)

Snippet

Sponsor: OHSU Knight Cancer Institute | Conditions: Castration-Resistant Prostate Carcinoma, Hormone-Resistant Prostate Cancer | Phase 2 | Status: ACTIVE_NOT_RECRUITING | Results posted: 2025-01-20